Pipeline

Current Clinical Trials

Advanced Melanoma

TRIAL

PISCES/KEYNOTE-695
Multicenter Phase II, Open-Label Trial of Intratumoral pIL-12 Plus Electroporation in Combination with Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment 

OBJECTIVE

Evaluate the efficacy of the combination of KEYTRUDA® and TAVO in advanced metastatic melanoma patients that are progressing on pembrolizumab or nivolumab.

Status: RECRUITINGLEARN MORE

TRIAL

OMS-102
Open-label, Phase II, Multicenter Study of Enhancing Pembrolizumab Responses in Melanoma through Intratumoral pIL-12 Electroporation

OBJECTIVE

Assess the anti-tumor efficacy (defined as the best overall response rate using RECIST v1.1) and safety of the combination of plasmid interleukin-12 electroporation and pembrolizumab in patients with low tumor-infiltrating lymphocyte (TIL) melanoma†

†This is a collaboration with University of California, San Francisco

Status: NOT RECRUITINGLEARN MORE

 

Triple Negative Breast Cancer

TRIAL

OMS-140
Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients with Triple Negative Breast Cancer

OBJECTIVE

Evaluate the potential of intratumoral treatment with pIL-12 delivered via electroporation to promote a pro-inflammatory molecular and histological signature in patients with triple negative breast cancer

Status: RECRUITINGLEARN MORE

OMS-141/KEYNOTE-890
Intratumoral Delivery of Plasmid IL-12  and Pembrolizumab in Patients with Inoperable Locally Advanced or Metastatic TNBC

OBJECTIVE

Evaluate the combination of intratumoral pIL-12  with pembrolizumab in TNBC patients with inoperable locally advanced or metastatic TNBC who have progressed on more than one line of prior therapy.

Status: PLANNEDLEARN MORE